Physician profile

Sun Moon Kim

Cardiovascular Disease · Pinehurst, NC

NPI 1649563834

$13,567.57

in general payments reported to CMS, 2019-2025

42 companies · $1,554 in 2025

The $1,554 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,824.20

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $3,730.99 2019-2024 Coroflow, Mitraclip, Cardiomems
Boston Scientific Corporation $2,689.60 2019-2025 Watchman Flx, Watchman Access System, Watchman
Medtronic Vascular, INC. $1,640.18 2019
Edwards Lifesciences Corporation $852.16 2019-2025 Sapien 3 Ultra Resilia, Pascal
Abiomed $753.53 2020-2025 Impella
Scpharmaceuticals INC. $448.91 2023-2024
Astrazeneca Pharmaceuticals Lp $435.04 2020-2025 Farxiga, Wainua
E.R. Squibb & Sons, L.L.C. $350.74 2022-2025 Camzyos
Irhythm Technologies, INC. $306.78 2021-2024 Zio Monitor, Zio Xt Patch
Inari Medical, INC. $285.77 2023-2024 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Boehringer Ingelheim Pharmaceuticals, INC. $282.07 2021-2025 Jardiance
Novartis Pharmaceuticals Corporation $220.10 2021-2025
Medtronic, INC. $201.28 2021-2024 Telescope, Onyx Frontier, Linq II
Angiodynamics, INC. $132.49 2019-2025 Angiovac
Pfizer INC. $131.83 2022-2025
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $126.22 2025 Repatha
Janssen Pharmaceuticals, INC $104.85 2022-2024 Xarelto
Merck Sharp & Dohme LLC $99.69 2021-2024 Verquvo
W. L. Gore & Associates, INC. $90.86 2019-2021
Philips North America LLC $58.29 2025 Coronary Other
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $55.57 2023-2025 Lifevest
Cvrx, INC. $54.85 2022-2025 Barostim Neo System
Bayer Healthcare Pharmaceuticals INC. $45.05 2025
Shockwave Medical, INC $42.38 2025
La Jolla Pharmaceutical Company $38.17 2024 Giapreza
Lexicon Pharmaceuticals, INC. $38.10 2023-2024 Inpefa
Celgene Corporation $37.17 2024 Camzyos
Biosense Webster, INC. $33.70 2022
Daiichi Sankyo INC. $29.09 2023 Injectafer
Chiesi USA, INC. $27.54 2022
Vital Connect, INC $23.66 2022
Bolton Medical INC $22.59 2022
Novo Nordisk INC $21.61 2025
Baxter Healthcare $19.92 2024 Renal - Acute
Atricure, INC. $19.81 2022
Teleflex LLC $19.75 2025 Vascband
Stryker Corporation $19.60 2025 N/A
Cardiva Medical, INC. $18.64 2023 Cardiva Vascade 6/7f Vcs
Alnylam Pharmaceuticals INC. $17.42 2025 Onpattro
Cardiovascular Systems INC. $17.07 2020-2021
Bridgebio Pharma, INC. $13.69 2025 Attruby
B. Braun Interventional Systems INC. $10.81 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sun Moon Kim

$13,567.57

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $1,554 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/808698/sun-moon-kim

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.